Matthew R Allen1,2,3,4, Mohammad W Aref5. 1. Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, USA. matallen@iupui.edu. 2. Department of Medicine/Division of Nephrology, Indiana University School of Medicine, Indianapolis, IN, USA. matallen@iupui.edu. 3. Department of Biomedical Engineering, Indiana University-Purdue University of Indianapolis, Indianapolis, IN, USA. matallen@iupui.edu. 4. Roudebush Veterans Administration Medical Center, Indianapolis, IN, USA. matallen@iupui.edu. 5. Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, USA.
Abstract
PURPOSE OF REVIEW: Bisphosphonates (BPs) have long been the gold-standard anti-remodeling treatment for numerous metabolic bone diseases. Since these drugs are excreted unmetabolized through the kidney, they are not recommended for individuals with compromised kidney function due to concerns of kidney and bone toxicity. The goal of this paper is to summarize the preclinical BP work in models of kidney disease with particular focus on the bone, kidney, and vasculature. RECENT FINDINGS: Summative data exists showing positive effects on bone and vascular calcifications with minimal evidence for bone or kidney toxicity in animal models. Preclinical data suggest it may be worthwhile to take a step back and reconsider the use of bisphosphonates to lessen skeletal/vascular complications associated with compromised kidney function.
PURPOSE OF REVIEW: Bisphosphonates (BPs) have long been the gold-standard anti-remodeling treatment for numerous metabolic bone diseases. Since these drugs are excreted unmetabolized through the kidney, they are not recommended for individuals with compromised kidney function due to concerns of kidney and bone toxicity. The goal of this paper is to summarize the preclinical BP work in models of kidney disease with particular focus on the bone, kidney, and vasculature. RECENT FINDINGS: Summative data exists showing positive effects on bone and vascular calcifications with minimal evidence for bone or kidney toxicity in animal models. Preclinical data suggest it may be worthwhile to take a step back and reconsider the use of bisphosphonates to lessen skeletal/vascular complications associated with compromised kidney function.
Entities:
Keywords:
Anti-resorptive agents; Bone mechanics; Bone remodeling; CKD; Renal osteodystrophy; Vascular calcification
Authors: S Moe; T Drüeke; J Cunningham; W Goodman; K Martin; K Olgaard; S Ott; S Sprague; N Lameire; G Eknoyan Journal: Kidney Int Date: 2006-06 Impact factor: 10.612
Authors: Christopher L Newman; Neal X Chen; Eric Smith; Mark Smith; Drew Brown; Sharon M Moe; Matthew R Allen Journal: Bone Date: 2015-04-17 Impact factor: 4.398
Authors: Koba A Lomashvili; Marie-Claude Monier-Faugere; Xiaonan Wang; Hartmut H Malluche; W Charles O'Neill Journal: Kidney Int Date: 2009-01-07 Impact factor: 10.612
Authors: Elizabeth A Swallow; Mohammad W Aref; Corinne E Metzger; Spencer Sacks; Demi R Lehmkuhler; Neal Chen; Max A Hammond; Paul R Territo; Thomas L Nickolas; Sharon M Moe; Matthew R Allen Journal: Bone Date: 2019-07-09 Impact factor: 4.398
Authors: E A Swallow; M W Aref; N Chen; I Byiringiro; M A Hammond; B P McCarthy; P R Territo; M M Kamocka; S Winfree; K W Dunn; S M Moe; M R Allen Journal: Osteoporos Int Date: 2018-06-11 Impact factor: 4.507
Authors: P Evenepoel; J Cunningham; S Ferrari; M Haarhaus; M K Javaid; M-H Lafage-Proust; D Prieto-Alhambra; P U Torres; J Cannata-Andia Journal: Osteoporos Int Date: 2021-06-15 Impact factor: 4.507